

Company number: 7487432
Charity number: 1139869
Charity number Scotland: SCO44260



Sarcoma UK

Report and Financial Statements

For the Year Ended 31 March 2015

CONTENTS

	Page
What we do	3
Chair of Trustees and Chief Executive's Statement	4
Reference and Administrative Details	5
Report of the Trustees:	6-16
Objectives and Activities	
Achievements and Performance	
Governance, Structure and Management	
Legal entity	
Charitable objects	
Trustees – appointment and induction	
Organisational structure	
Volunteers	
Staff	
Risk Assessment	
Grant making policy	
Public benefit	
Working with others	
Financial Review	
Statement of Trustees' Responsibilities	
Thanks/Acknowledgements	
Auditors Report	17-18
Statement of Financial Activities (SOFA)	19
Balance Sheet	20
Notes to the Financial Statements	21-26

What we do

- We initiate change to raise sarcoma **awareness** and improve standards of treatment and care.
- We seek answers through **research**.
- We provide **support & information** for the sarcoma community.

Sarcoma UK is the only charity in the UK that focuses on all types of sarcoma. That's our purpose; that's why we are here.

- We are here to provide **credible, high quality information** about sarcoma to everyone affected by sarcoma. We are here to lend support and answer questions.
- We are here to **improve survival rates** by promoting early diagnosis and ensuring all people diagnosed with sarcoma are aware of their treatment pathway.
- We are here to **educate GPs and the public** on the signs and symptoms of sarcoma so people are diagnosed earlier.
- We are here to **ensure that people are not alone** during their diagnosis and treatment. By working with all members of the sarcoma community – patients, carers, supporters, health professionals and researchers – we share information and work collaboratively.
- We are here to **get sarcoma on the political agenda**. We empower people through our Sarcoma Voices programme, to ask questions about this rare cancer and get their voices heard.
- We are here to **guide and inspire supporters** to maximise their fundraising and show them exactly how we spend their money.
- **Ultimately we are here to find a cure for sarcoma**. The research we fund adds to the knowledge base in sarcoma, provides evidence to support changes to practice, and supports breakthroughs.

"We would never have had the amazing treatment that he has received and support if it wasn't for the likes of Sarcoma UK." – Maddie Eaton, partner of sarcoma patient and fundraiser, May 2014.

"I've been able to see the direct result of fundraising as recently a guide was published for patients with my type of sarcoma which will prove invaluable to those facing their own diagnosis" – Claire McIntyre, sarcoma patient and fundraiser.

What is sarcoma?

- Sarcomas are rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues
- There are around 100 different sub-types of sarcoma

The current sarcoma landscape

- About 3,800 new cases of sarcoma are diagnosed each year in the UK which makes up approximately 1% of all cancer diagnoses
- 3,330 people are diagnosed with a soft tissue sarcoma (including GIST)
- 500 people are diagnosed with a bone sarcoma
- In general, patients with a bone or soft tissue sarcoma diagnosis tend to be younger than the majority of cancer patients
- 16% of bone or soft tissue sarcomas are diagnosed in patients less than thirty years of age, compared to around 2% of all cancers
- 37% of bone or soft tissue sarcoma patients are aged less than 50 years
- Sarcomas make up 15% of all childhood cancers (0-14 years)
- Sarcomas make up 11% of all cancer diagnoses in teenagers and young people (15-24 years)
- The five-year relative survival rate for all sarcomas is only 55% and overall survival is still poor compared to other countries e.g. Scandinavia and Italy, and other cancer types.

Chair of Trustees and Chief Executive's Statement

As Sarcoma UK approaches the £1million income level (forecast 2015/16), the Board of Trustees wishes to thank everyone in the sarcoma community for their contribution to our progress during the past year. In 2014/15, we had ambitious plans that were fully delivered with professionalism and commitment by our small team of seven staff. Our income predictions were modest and we were delighted to end the year with an income level that greatly exceeded our expectations. This enables us to commit more funds to research into sarcoma; to supporting more people affected by sarcoma and their families; and to raising more awareness of sarcoma amongst the public.

The continuing progress of Sarcoma UK as the only national charity for all types of sarcoma was seen clearly in our achievements this year, including many new areas of development for us. We researched and published our first campaign report about the experiences of women with gynaecological sarcoma, raising questions about the quality of treatment and care women receive, and highlighting the difficulties women face reaching sarcoma specialist services. It was a challenging hard hitting report which made waves within the gynaecological professional world. However, it was also a vital piece of work giving a strong voice to women with gynaecological sarcoma. We will continue to build our campaigning voice in 2015/16 with the launch of a report containing results of our first national survey of sarcoma patients in England and Scotland.

We are pleased to report progress towards our strategic goal: "More people will survive sarcoma" through the national launch of our On the Ball GP awareness campaign during Sarcoma Awareness Week in June 2014. Over 1000 supporters throughout the UK ordered a pack containing a golf ball key ring and Diagnostic Tool to give to their GP to help them understand more about sarcoma, and we are very grateful for this support and engagement.

Sarcoma UK is the only charity in the UK providing a comprehensive support and information service dedicated to sarcoma. In 2014/5, our services were used by double the number of people than in the previous year. We will invest in 2015/16 to extend this into the provision of expert, specialist and individualised support for people affected by sarcoma.

The Board of Trustees are very aware that Sarcoma UK's ability to deliver our ambitious goals depends on our continued engagement with the sarcoma community. We highly value all our dedicated supporters who help the charity in multiple ways and hope that you will continue to support us in our work over the coming years.

Thank you.

Karen Delin
Chair of Trustees

Lindsey Bennister
Chief Executive

Sarcoma UK
Reference and administrative details
For the year ended 31 March 2015

Company number	7487432 (Limited by guarantee in England and Wales)
Charity number	England and Wales (1139869) Scotland (SCO44260)
Registered Office	49-51 East Road London N1 6AH
Trustees	Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows: Peter Jay Chair (resigned October 2014) Karen Delin Chair (from October 2014) Nicky Mellows (resigned October 2014) David Thompson (appointed June 2014) Lesley Abraham Dr Jane Barrett Glyn Wilmshurst Leigh Hibberdine Professor Rob Grimer Ian Hughes Sharon Reid Helen Stradling Dr Jeff White Sam Whittam
Patron	Richard Whitehead MBE
Honorary President	Roger Wilson CBE
Chief Executive	Lindsey Bennister
Company Secretary	Karen Wines (Director of Finance & Resources)
Bankers	CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4JQ Lloyds TSB, National Clubs & Charities, PO Box 1000, BX1 1LT
Solicitors	Bates Well & Braithwaite LLP 2-6 Cannon Street London EC4M 6YH
Auditors	Sayer Vincent Chartered accountants and statutory auditors Invicta House 108-114 Golden Lane London EC1Y 0TL

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

The Trustees present their report and the audited financial statements for the year ended 31 March 2014. Reference and administrative information set out on page 5 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association and the Statement of Recommended Practice - Accounting and Reporting by Charities (SORP 2005).

Objectives and Activities

Sarcoma UK is the only cancer charity in the UK focusing on all types of sarcoma.

Our Mission

To increase knowledge and awareness of sarcoma through ground breaking programmes that inspire involvement and transform the landscape for everyone affected by sarcoma.

Our Goals

1. More people will survive sarcoma.
2. More will be known about the causes of sarcoma.
3. Everyone affected by sarcoma will have access to the best treatment and care.

Achievements and Performance

Sarcoma UK's achievements against objectives for the year are set out below. Our activities and income increased significantly during the year with £964,709 raised compared to £760,967 in 2013/14. The Trustees wish to thank everyone who has supported the charity this year and contributed to its achievements.

Strategic priorities for the year and achievements:

Priority 1: Initiate change to raise awareness and improve care

Sarcoma cancer is not widely known by the public. In our first market research poll carried out in January 2015 (of 1000 people), we found that 53% of the public had never heard of sarcoma; and only a quarter of the public were able to identify sarcoma as a type of cancer. This is why our priority is to increase awareness of the signs and symptoms of sarcoma with the public and health professionals. Earlier diagnosis will ultimately save lives and GPs play a vital role in helping to make this happen. The poll will be carried out annually to track public awareness of sarcoma against this baseline information.

The experiences of sarcoma patients provide us with important insights into how care can be improved within the NHS, and these experiences inform all of our work.

Objective

Launch a national GP education programme to bring about earlier diagnosis of sarcoma, building on the learning from a regional pilot project in 2013/14.

What we achieved

Sarcoma Awareness Week 2014 marked the launch of our national GP awareness campaign. We asked the sarcoma community to individually take an On the Ball pack to their own GP at their next appointment. The pack contained a personal letter from the patient; clinical information about sarcoma; a Diagnostic Tool to help GPs identify the red flag symptoms of sarcoma; and a golf ball key ring as a reminder of the size of a lump that may indicate sarcoma. The campaign, backed by Sarcoma UK Patron, Paralympic gold medallist Richard Whitehead MBE and sarcoma patients, achieved TV, radio and press coverage including local BBC, ITV and the Daily Mail.

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

In 2014/15, 1,034 packs were distributed throughout the whole of the UK, with positive feedback from GPs.

In 2015/16, we will expand our work on early diagnosis to provide and participate in GP training and Continued Professional Development programmes.

Objective

Increase our understanding of sarcoma patients' experiences and provide expert patient input to NHS sarcoma services.

What we achieved

We had become increasingly aware of the often devastating impact of gynaecological sarcoma (a sub-type of sarcoma affecting almost 300 women each year) through hearing the experiences of women and their families who use our support and information services. Anecdotal evidence indicated that many women were not able to access the best treatment and experienced delays in referral to sarcoma specialist services until the cancer was too far advanced for treatment. In 2014 we carried out an in-depth survey of women with gynaecological sarcoma, leading to the production of our first campaign report "Gynaecological Sarcoma: The Hidden Cancer" in early 2015. The report was presented at the British Sarcoma Group annual conference and distributed to gynaecology and gynaecological oncology professionals, and health policy makers. The experiences of women in the report also informed an investigative news story by Channel 4 News, involving Sarcoma UK's chief executive. **In 2015/16, we will continue to campaign for a consensus between gynaecological oncology and sarcoma specialist health professionals on the treatment and care of women with gynaecological sarcoma.**

In 2014, we engaged Quality Health (a company that delivers the National Cancer Patient Experience Survey – NCPES) to carry out a large scale survey of sarcoma patients on behalf of Sarcoma UK. We were able to talk directly to 1000 people living with all types of sarcoma in England and Scotland and ask them questions to understand more about their experiences. A steering group of patients, clinicians and statisticians helped shape the content of the questionnaire. **In 2015/16, we will publish a detailed report of sarcoma patient experiences in England and Scotland, which will act as a comprehensive evidence base to inform our work.**

Through our Sarcoma Voices programme, we supported people with personal experience of sarcoma to participate in sarcoma research and policy groups including the NHS England Sarcoma Clinical Reference Group, National Cancer Research Institute Sarcoma Clinical Studies Group, and the National Cancer Intelligence Network Sarcoma Site Specific Clinical Reference Group. Members of Sarcoma Voices contributed to the many policy responses that Sarcoma UK produced during 2014/15.

Priority 2: Seek answers through research

Sarcoma is a complex disease that requires high levels of investment to bring about breakthroughs in understanding the causes, developing new treatments and ultimately preventing sarcoma. We invest in high quality, innovative research throughout the UK.

Objective

To expand our sarcoma grants programme.

What we achieved

Sarcoma UK runs a UK-wide grants programme dedicated specifically to sarcoma. We are committed to funding high-quality, peer-reviewed research that benefits sarcoma patients. In 2014/15, we awarded our largest call for proposals to date with a £250,000 investment allocated by the Board of Trustees. The aim was to attract larger applications and also to fully fund selected applications. This resulted in five new grants awarded in the first quarter of the financial year (2014/15), bringing the total amount of research funded by Sarcoma UK to £675,836, with 16 projects funded.

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

We made five new awards this year:

1. Dr Tim Forshew, University College London: Assessing the potential of circulating tumour DNA as a new biomarker for low grade bone and soft tissue neoplasms. £25,680.
2. Dr Paul Huang, Institute of Cancer Research: Dissecting the mechanisms of pazopanib resistance in soft tissue sarcoma. £31,301.
3. Dr Barbara Tanos, Institute of Cancer Research: Role of TTBK2 and cilia in sarcoma progression. £58,415.
4. Dr Clare Turnbull, Institute of Cancer Research: Studies of genetic susceptibility using exome sequencing in patients with sarcoma and an additional primary tumour. £92,635.
5. Dr Gareth Veal, Northern Institute for Cancer Research, University of Newcastle: Study to investigate correlations between age-dependant pharmacokinetic variation, side-effects of chemotherapy and biomarkers of toxicity in Ewing's sarcoma. £43,490.

We continued to fund previous research commitments:

Grants awarded in 2012/13:

- Dr Henning Wackerhage, University of Aberdeen: "TAZ & rhabdomyosarcoma: TAZ expression in human samples, TAZ transformation of myoblasts and YAP/TAZ drug discovery.
- Mr Craig Gerrand, Newcastle Upon Tyne Hospitals NHS Trust: "Evaluation of physical functioning in adults treated for bone and soft tissue sarcomas – a feasibility study of two new technologies.
- Professor Adrienne Flanagan. University College London: "New therapeutic agents for chordoma".

Grants awarded in 2011/12:

- Dr Beatrice Seddon, University College London: "The International Sarcoma Kindred Study: a global multi-site prospective cancer genetics study".

We are pleased to report that Sarcoma UK-funded grants have generated the following outputs in 2014/15:

Presentations:

- Next generation RNA and DNA sequencing identifies expressed mutant pathways in pleiomorphic high grade sarcoma. 2015 British Sarcoma Group in Nottingham (Professor Ted Hupp)
- The Role of the Hippo Pathway in Rhabdomyosarcoma at the Scottish Sarcoma Network meeting, Dundee, May 2014 (Dr Henning Wackerhage)
- Invited presentation: Persistent YAP hyperactivity drives CINSARC gene expression and results in tumours with complex genomes at the Keystone Hippo meeting, Taos, May 2014 (Dr Henning Wackerhage)
- Invited Speaker at the 34th European Society for Surgical Oncology Congress. Liverpool, UK. 2014. Angiosarcoma after breast cancer surgery (Dr Robin Young)

Publications:

- *Quantitative Proteomic Profiling of Pleomorphic Human Sarcoma Identifies CLIC1 as a Dominant Pro-Oncogenic Receptor Expressed in Diverse Sarcoma Types.* Murray E, Hernychová L, Scigelova M, Ho J, Nekulova M, O'Neill J R, Nenutil R, Vesely K, Dundas S R, Dhaliwal C, Henderson H, Hayward R L, Salter D M, Vojtěšek B, Hupp T R. *J Proteome Res.* 2014 May 2;13(5):2543-59. doi: 10.1021/pr4010713. Epub 2014 Apr 9 (Professor Ted Hupp)
- *The Hippo Transducer YAP1 Transforms Activated Satellite Cells And Is A Potent Effector of Embryonal Rhabdomyosarcoma Formation.* Tremblay A M, Missiaglia E, Galli G G, Hettmer S, Urcia, R, Carrara M, Judson R N, Thway K, Nadal G, Selfe J L, et al. (2014). *Cancer Cell* 26, 273-287 (Dr Henning Wackerhage)

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

- *The Hippo signal transduction pathway in soft tissue sarcomas*. Mohamed A D, Tremblay A M, Murray G I and Wackerhage H (2015). BBA cancer, epub (Dr Henning Wackerhage)
- *Canine Angiosarcoma: A tumour model*. Young R J, Flewers T, Staton C A, Woll P J, Reed MWR, Brown N J. 64th Annual British Microcirculation Society Meeting. Bristol, UK. 2014. Poster presentation (Dr Robin Young)

Research funding generated:

- 2014 Friends of Anchor. Wackerhage H, Stevenson D, Turbitt J, Urcia R: Does the Yap oncogene worsen cancer by inducing chromosomal instability and oncogene copy number gains? £9,870 (Dr Henning Wackerhage)
- 2014 Friends of Anchor. Wackerhage H, Collie-Duguid E, Murray G, and Urcia R: Yap, Taz, and Vgl13: How does this trio drive tumorigenesis in two types of rhabdomyosarcoma? £9,200 (Dr Henning Wackerhage)

In 2015/16, we will continue to increase the amount of funds invested into research; and improve our communications to supporters about the research we fund, including holding a national event showcasing Sarcoma UK's funded research.

Priority 3: Support the sarcoma community and provide information

Objective

Reach more people affected by sarcoma through our information and support services.

What we achieved

In 2014/15, we significantly increased our range of information and support for people affected by sarcoma and the ways that it can be accessed, resulting in many more people using our services.

An increasing number of people are using our 'About Sarcoma' pages on the website to help them learn about their diagnosis and treatment. In 2014/15, the number of people using our website sarcoma information increased by 75% to over 68,500.

In addition, our printed booklets remain very popular, with over 3000 copies of our three guides for people with newly diagnosed sarcoma; GIST; and gynaecological sarcoma sent out in 2014/15. The guides are Information Standard accredited, a mark of quality in health information, and offer people space to keep notes about their treatment.

We also expanded our range of patient information during 2014/15. As part of an innovative collaboration between patients, support groups, health professionals, bone sarcoma specialist centres, and rehabilitation specialists, Sarcoma UK's website became the host of a national 'information hub' on rehabilitation for people with sarcoma. Since its launch in November 2014, over 2000 people have visited the hub to find out about rehabilitation services available to them. We also produced a new patient guide about gynaecological sarcoma.

This year, Sarcoma UK was involved in 20 events held during the year that provided information and support to patients, including Living Well with Sarcoma events in conjunction with sarcoma specialist centres, sarcoma support group meetings, regional sarcoma conferences, and patient/professional education events in Scotland, Northern Ireland and England. We provided face-to-face information and support to over 500 people affected by sarcoma.

We also saw a significant increase in personal and individualised requests for support by telephone and email. This year, enquiries to Sarcoma UK from patients and their families doubled from the previous year.

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

We strengthened and expanded our network of regional sarcoma support groups across the UK with the aim of having a support group associated with each sarcoma specialist centre. Through this thriving network, we supported 600 people affected by sarcoma. We also helped 1 new regional sarcoma group to get established, and provided financial support and advice to 13 existing groups.

In 2015/16, we will expand our support and information services to provide tailored, individualised support and information to people with sarcoma, their families and supporters.

Other priorities

Communications

Media

Our reputation is growing within the media as the first organisation to contact for expert comments on all sarcoma-related issues. This year, we have received many more enquiries from local and national journalists in TV, radio, press and digital news. Highlights of the year include: Channel 4 News, The Times (Aberdeen research project); Guardian Online (Miniature Ink); and digital media support from Premier League rugby unions clubs, Saracens and Northants Saints.

In total we generated 180 individual articles which represents an average of 3 mentions a week and a total audience reach of over 30 million. This is mainly down to our supporters using our key messages and sharing their personal story with their local media, in turn raising public awareness of sarcoma. By providing supporters with the tools to contact their local media, we can maximise awareness and minimise the funds spent on PR activities.

In October, Channel 4 broadcast an exclusive feature about power morcellation (a treatment used for gynaecological problems that may be linked to the spread of undiagnosed gynaecological sarcoma) which included an interview with our Chief Executive, Lindsey Bennister. Channel 4's Health Correspondent, Victoria MacDonald worked with Sarcoma UK to produce this powerful feature using our case studies and evidence from our report "Gynaecological Sarcoma: The Hidden Cancer". It was aired on prime-time Channel 4 news (22 Oct).

Digital

We made digital media a priority this year. Using our website and social media as a platform to reinforce Sarcoma UK's key messages, we also used digital media as a tool to celebrate and promote our supporters' activities, efforts and achievements.

Our donor-centric and personalised approach in our Facebook and Twitter accounts has led to a 45% increase in followers.

Social media proved the most effective way of promoting our On the Ball campaign with 29% of supporters ordering a GP pack because they had seen the call to action on Facebook or Twitter. The largest On the Ball social media post reached 9,752 people with 123 shares.

The number of visits to the Sarcoma UK website increased by 41% during 2013/14 totalling 357,600 page views from 111,984 users (compared to 253,785 from 72,000 users in 2013/14). This shows the increasing popularity of our website as a way of engaging with the charity and sourcing information and support.

We aim to reach as many people as possible through our printed quarterly publication *Connect*, in order to inform and inspire newly diagnosed patients and help them feel less isolated. Throughout this year, sign-ups to receive *Connect* by post increased by 33%.

In 2015/16, we will invest significantly in our website, so that it provides greater support and is more

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

responsive to the needs of people with sarcoma, their families and our supporters. We will engage with our readers about the content and distribution of Connect to ensure it reflects their needs and preferences; and we will introduce new ways to communicate with our supporters to keep them informed about our work.

Priority 4: Build a strong charity

The commitment and dedication from our current supporters, and the increasing number of supporters who are new to the charity, has helped us to surpass our income target for the year. We cannot do the work we do without this support from the sarcoma community. From head-shaves to fancy dress; from open water swims to shaking a tin at sporting events; and personal challenges like climbing the world's tallest mountain, our supporters are highly successful in raising much needed funds and awareness of sarcoma. For example, supporter Paula Magnus raised over £21,000 at a glamorous ball at Epsom Racecourse in memory of her husband, Dean.

Our connection with the rugby world was a consistent theme in 2014/15. Northampton Saints Rugby Club fan, Luis Ghaut was diagnosed with osteosarcoma. Luis' story touched everybody he met and funds were raised by his local community towards his treatment and charities including Sarcoma UK. Sadly, Luis passed away in September. His family maintain close links with Sarcoma UK and visited us to present a cheque for £10,000. They continue to take part in events and challenges in Luis' memory and to play a significant role in raising the profile of sarcoma.

Sarcoma UK was nominated as match-day charity by Saracens Rugby Club at an Aviva Premiership game against Bath by a supporter with personal experience of sarcoma who worked for Saracens. Our team of volunteers talked to fans and collected donations throughout the event.

To meet increased demand from supporters, we have extended our events and challenges portfolio. After careful analysis, we committed to buying 14 official places in the London Marathon and 24 places in the Prudential Ride 100. This has resulted in a good return on investment with both events exceeding expectations, raising a total of £76,000. The London Marathon in particular is very popular and Team Sarcoma is boosted each year by runners who have acquired their own places in the ballot, thereby adding extra value and saving the charity the cost of the place. In 2014, we held our first post-marathon party at the wonderful rooftop terrace of the Transport for London building close to the finish line, where the space was made available to us at no cost through a Sarcoma UK supporter.

The 17-strong Sarcoma UK team taking place in our first Prudential Ride London-Surrey in August 2014 bravely battled through hurricane conditions to complete the gruelling circuit, cheered on by friends and family at cheering posts along the route. We would particularly like to thank the Super C's, who take up this challenge annually in memory of Derek Watkins.

This year, we have started to diversify our income streams including building links with corporate organisations and entering partnerships with other charities. We are privileged to receive annual support from investment company, The Analyst, who pledge a percentage of their annual profits to Sarcoma UK, in memory of their founder Jonathan Scriven.

We highly value the ongoing partnership with our friends at The Boom Foundation in Northern Ireland. This thriving charity, founded and run by Leona Rankin in memory of her fiancée Philip, provides support to people affected by sarcoma in Northern Ireland. The Boom Foundation pledge 50% of their fundraising to Sarcoma UK to support our research programme, and in 2014/15 donated £25,000 to Sarcoma UK.

Sarcoma UK receives some financial support from pharmaceutical companies. Sarcoma UK's Board of Trustees have approved a policy setting out the framework and principles behind Sarcoma UK's relationship

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

with the pharmaceutical industry, which is available publicly on the charity's website. Donations from pharmaceutical companies in 2014/15 represent 1% of Sarcoma UK's income for the year.

We strive to keep the costs of raising money to a minimum. This year, for every £1 spent on fundraising £5.53 was raised.

We would like to thank all the people who have fundraised for us during this year (and beyond). Your involvement is helping us to transform the landscape for everyone affected by sarcoma.

In 2015/16, we will further diversify our fundraising streams to ensure a sustainable funding base is in place for the charity, as well as increase the communications with our supporters to keep them fully informed of our work, achievements, and how their donations have been used.

Governance, Structure and Management

Legal Entity

Sarcoma UK is a charity registered in England and Wales with the Charity Commission on 17 January 2011, and registered as a charity in Scotland on 12 September 2013. Its governing documents are its memorandum and articles of association. Sarcoma UK is also a company limited by guarantee incorporated with Companies House on 10 January 2011.

Sarcoma UK is sole corporate Trustee of former charity The Sarcoma Trust.

Charitable Objectives

The objectives of the charity are to promote and protect the physical and mental health of patients with bone and soft tissue sarcomas in the United Kingdom through the provision of information, support, education and practical advice to them, their families and their carers; the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; to advance the education of the general public in all areas relating to sarcoma.

Trustees Appointment and Induction

Sarcoma UK recognises that having an effective Board of Trustees, with appropriate knowledge, skills and influence, is vital to achieving its Goals. During 2013, a number of Trustees indicated that they were planning to step down when the end of their term of office came to an end (September 2014). In preparation for this, and to strengthen the breadth of expertise within the Board, new Trustees were appointed during 2013 (see below). New Trustees are recruited through a variety of networks and contacts and appointed by the Board for a three-year term, after which they are eligible for re-election for a further three years.

All new Trustees receive Sarcoma UK's governing document, strategy and business plan, published accounts and minutes of previous Board of Trustee meetings, as well as Charity Commission guidance on effective governance. Each Trustee spends time with the Chief Executive as part of their induction.

Organisational Structure

The Board of Trustees set the strategic direction of Sarcoma UK and approves the main policies of the charity. It appoints and directs the Chief Executive, monitors performance and identifies and manages the major risks facing the charity. The Board meets four times a year.

The Board delegates responsibility for the running of the charity to the Chief Executive with clearly communicated and recorded executive limits. The Chief Executive is responsible and accountable for achieving Sarcoma UK's strategic objectives.

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

The Chief Executive is supported by a small expert team of staff. The total number of staff employed at 31 March 2015 was 7 (including 1 part-time).

Volunteers

The Trustees recognise the valuable contribution made by volunteers to Sarcoma UK and wish to record their gratitude for this commitment. These include members of Sarcoma UK's Research Advisory Committee; sarcoma support group leaders; managers of online support services; Sarcoma UK's Information Review Panel; individuals and families who have provided their stories for use as case studies; everyone who has undertaken fundraising & awareness raising in their communities; and everyone who has set up information stands and cheering stations at events and challenges. We particularly want to thank Glenys Stittle, our office volunteer, for her dedication and support on a weekly basis. In accordance with accepted practice, no amounts are included in the financial statements to reflect the value of work undertaken by volunteers.

Staff

The Trustees are grateful to the small staff team for the outstanding work they do on behalf of people affected by sarcoma. This year, we invested in a Head of Research role to help build for the future.

Risk Assessment

The Trustees have a risk policy in place and during this year a risk assessment process has been established. Through the process major strategic risks are identified, assessed against their likely impact and where appropriate, measures are implemented to mitigate the risks. In our risk assessment model risks are categorised under the headings; Governance, Financial, Operational, Environmental and External Factors, Compliance and Charitable Objectives. The risk model has been reviewed by the Trustees and they are satisfied that appropriate systems are in place to mitigate major risks. The model is regularly reviewed by the management team and presented to the Board of Trustees annually.

Grant Making Policy

Our sarcoma grants programme involves annual calls for proposals which are publicised across the sarcoma research community. The applications we receive then undergo a rigorous peer review process in line with Association of Medical Research Charities (AMRC) guidelines to identify the best quality sarcoma research projects in centres of excellence across the UK. Meetings of our Research Advisory Committee and Board of Trustees select and approve the final grants.

Sarcoma UK has a Conflicts of Interest policy in place for the Research Advisory Committee whereby all members of the committee are required to provide an annual declaration of potential conflicts of interest. The policy also sets out the conditions for automatic exclusion from participation in funding decisions for members who have conflicts of interest, and this policy is followed rigorously at meetings.

Our current research strategy states that no area of research is given greater priority over any other but we will always award competitively, on the basis of the scientific quality of the proposed studies. We wish to increase the sum total of sarcoma research in the UK. To do this with the limited funds we currently have available, we are willing to be creative by, for example, co-funding projects or awarding 'pump-priming' grants.

Public Benefit

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

Working with Others

Sarcoma UK recognises that progress towards our goals is maximised when working collaboratively with others who share an interest in improving the outcomes for people affected by sarcoma. As the only UK charity focusing on all types of sarcoma, we aim to work collaboratively with the whole sarcoma community to achieve our vision for the future. Sarcoma UK has relationships with the following organisations:

British Sarcoma Group; National Sarcoma Forum (of specialist nurses); NCIN Sarcoma Site-Specific Clinical Reference Group; Public Health England West Midlands Knowledge & Intelligence Team (sarcoma); NHS England Sarcoma Clinical Reference Group; Scottish Sarcoma Network; Boom Foundation (Northern Ireland); Bone Cancer Research Trust; Chordoma UK; GIST Support UK; Guy Francis Bone Cancer Research Fund; Sarcoma Patients EuroNet; National Cancer Research Institute; Association of Medical Research Charities; Cancer 52; Cancer Campaigning Group; The Specialised Healthcare Alliance; and National Institute for Health & Care Excellence.

Financial Review

As described earlier in this report, we have made excellent progress against our objectives for the year. We succeeded in raising £964,709, an increase of 27% from the previous year (2014: £760,967). This is significantly higher than our forecasted income for the year (26%), putting the charity in a strong financial position. The Statement of Financial Activities shows that the main source of income is voluntary with investment income remaining low due to low interest rates.

Income sources are mainly unrestricted voluntary donations from individuals and families who have a personal connection with sarcoma and from fundraising through events and challenges. The principle sources of funding were community and sponsored event fundraising (50%), donations in memory (17%), gift aid (10%) and corporate donations (8%).

Our overall expenditure on charitable activities (research, information, support and awareness) increased significantly by 77% to £610,119. This reflects the increased expenditure on research (£262,469), due to no research grants being awarded in the previous year.

Governance costs include Trustees training and development, meeting costs, and travel expenses for Trustees to represent the charity externally at meetings, conferences and fundraising presentations.

The growth in our income is a direct result of the investment in our fundraising and marketing department where we have seen increased activity and achievements. Although the cost of generating funds has increased by 42%, it has decreased from 25% of total expenditure in 2013/14 to 22% this financial year, remaining comfortably within the sector average. In addition to higher numbers of supporters, each individual supporter has raised significantly more funds than in previous years. This is due to the increased support given to individual supporters by the charity during their 'supporter journey'.

An operating surplus of £160,943 (2014: surplus of £275,397) was made this year and increases the total charity funds to £872,469 (2014: £711,526), of which £69,101 are restricted to infrastructure development.

Reserves Policy

The Trustees agreed the following statement about financial reserves at their meeting in October 2014.

"The level of reserves should be approximately equivalent to 8 months of overhead costs (plus current liabilities)."

The total funds of the charity at 31 March 2015 were £872,469 of which £69,111 is restricted. This leaves

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

a balance of £803,358 as unrestricted funds or what the Charity Commission define as 'free' reserves. The Trustees have agreed to designate £335,493 of these free reserves towards research grants in 2015/16, leaving a balance of £467,865. The level of reserves is equivalent to just over 8 months of overhead/running costs. This is approximately £440,000 for the forthcoming year, which will ensure uninterrupted services and delivery of our charitable objectives. The reserves policy will be reviewed annually to ensure they are adequate for the charities future operational needs.

Statement of Trustees' Responsibilities

The Trustees (who are also directors of Sarcoma UK for the purposes of company law) are responsible for preparing the report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently
- observe the methods and principles in the Charities SORP
- make judgements and estimates that are reasonable and prudent
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

Auditors

Sayer Vincent LLP have indicated their willingness to continue in office. A resolution proposing their re-appointment will be submitted at the Annual General Meeting.

The report of the Trustees has been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

The report was approved by the Board of Trustees on 17 September 2015 and signed on its behalf by:

.....
Karen Delin – Chair of Trustee

Sarcoma UK

Report of the Trustees

For the year ended 31 March 2015

ACKNOWLEDGMENTS

The Board of Trustees wishes to acknowledge the following people for their outstanding support of Sarcoma UK during the past year:

PATRON - Richard Whitehead MBE

HONORARY PRESIDENT - Roger Wilson CBE

Sarcoma UK Research Advisory Committee

Professor Ian Judson (Chairman) BSc MB BS MA MD FRCP (Chairman)

Head of Sarcoma Unit and Professor of Cancer Pharmacology, Royal Marsden Hospital, London

Professor Penella Woll (Vice Chair) BMedSci MB BS PhD FRCP

Professor of Medical Oncology, University of Sheffield

Professor Adrienne Flanagan MB PhD FMedSci

Professor of Musculo-Skeletal Pathology, University College London

Consultant Histopathologist, Clinical Lead, Royal National Orthopaedic Hospital, London

Professor Bass Hassan BSc DPhil FRCP

Professor of Medical Oncology, University of Oxford

Mr Sam Patton MB ChB FRCSEd FRCS

Consultant Orthopaedic Surgeon, New Royal Infirmary, Edinburgh

Dr Janet Shipley BSc PhD

Team Leader, Sarcoma Molecular Pathology, Institute of Cancer Research, London

Dr James Spicer MA FRCP PhD

Reader in Experimental Oncology, King's College London

Consultant in Medical Oncology, Guy's and St Thomas' NHS Foundation Trust

Dr Paula Wilson BSc MBChB (Hons) MRCP FRCR

Consultant in Clinical Oncology, University Hospitals Bristol

Mr Lee Jeys MB ChB MSc FRCS

Consultant Orthopaedic Surgeon, Royal Orthopaedic Hospital Birmingham

Individuals who have provided professional support

The following people have provided valuable professional support and advice to Sarcoma UK on a pro-bono basis.

- Kate Donachie (HR Business Partner, Work Services Directorate, Department for Work and Pensions)
- Edelman PR
- Mark Gould (Director, The Systems Management Company)
- Jonathan Rennison (Mentor, Institute of Fundraising)

Independent Auditors' Report

To the members of

Sarcoma UK

We have audited the financial statements of Sarcoma UK for the year ended 31 March 2015 which comprise the statement of financial activities, the balance sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company's members and Trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company's members and Trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members and Trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of Trustees and auditors

As explained more fully in the statement of Trustees' responsibilities set out in the report of the Trustees, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the report of the trustees to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:

- Give a true and fair view of the state of the charitable company's affairs as at 31 March 2015 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- Have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Independent Auditors' Report

To the members of

Sarcoma UK

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:

- The charitable company has not kept proper and adequate accounting records or returns adequate for our audit have not been received from branches not visited by us
- The financial statements are not in agreement with the accounting records and returns
- Certain disclosures of Trustees' remuneration specified by law are not made
- We have not received all the information and explanations we require for our audit
- The Trustees were not entitled to take advantage of the small companies exemption in preparing the report of the Trustees' and take advantage of the small companies exemption from the requirement to prepare a strategic report.

Catherine Sayer (Senior statutory auditor)

23 September 2015

for and on behalf of Sayer Vincent LLP, Statutory Auditors

Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL

Sayer Vincent LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006

Sarcoma UK

Statement of Financial Activities

For the year ended 31 March 2015

	Note	Unrestricted £	Restricted £	Total 2015 £	Total 2014 £
Incoming resources					
<i>Incoming resources from generated funds</i>					
Voluntary income	2	910,156	49,236	959,392	758,232
Investment income		<u>5,317</u>	<u>-</u>	5,317	<u>2,735</u>
Total incoming resources		<u>915,473</u>	<u>49,236</u>	964,709	<u>760,967</u>
Resources expended					
<i>Costs of generating funds:</i>					
Costs of generating voluntary income		172,295	1,216	173,511	121,843
<i>Charitable activities</i>					
Research		242,279	76,219	318,498	56,029
Information and support		109,941	1,537	111,478	116,588
Awareness and education		156,749	23,394	180,143	171,972
<i>Governance costs</i>		<u>20,076</u>	<u>60</u>	20,136	<u>19,138</u>
Total resources expended	3	<u>701,340</u>	<u>102,426</u>	803,766	<u>485,570</u>
Net movement in funds	4	214,133	(53,190)	160,943	275,397
Reconciliation of funds					
Total funds brought forward		<u>803,358</u>	<u>122,301</u>	711,526	<u>436,129</u>
Total funds carried forward	12	<u><u>1,017,491</u></u>	<u><u>69,111</u></u>	872,469	<u><u>711,526</u></u>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 12 to the financial statements.

Sarcoma UK**Balance sheet**

Company number: 7487432

As at 31 March 2015

	Note	£	2015 £	2014 £
Fixed assets				
Tangible fixed assets	7		<u>12,669</u>	<u>15,966</u>
Current assets				
Debtors	8	178,136		85,321
Cash at bank and in hand		675,381		728,900
Short term deposits		<u>301,656</u>		<u>-</u>
		1,155,173		814,221
Liabilities				
Creditors: amounts due within one year	9	<u>220,190</u>		<u>118,661</u>
Net current assets			<u>934,983</u>	<u>695,560</u>
Total assets less current liabilities			947,652	711,526
Creditors: amounts due in greater than one year	10		<u>75,183</u>	<u>-</u>
Net assets	11		<u>872,469</u>	<u>711,526</u>
Funds	12			
Restricted funds			69,111	122,301
Unrestricted funds				
Designated funds			335,493	250,000
General funds			<u>467,865</u>	<u>339,225</u>
Total charity funds			<u>872,469</u>	<u>711,526</u>

Approved by the trustees on 17 September 2015 and signed on their behalf by

Karen Delin - Chair of Trustees

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2015

1. Accounting policies

- a) The financial statements have been prepared under the historical cost convention and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities (SORP 2005).
- b) Voluntary income is received by way of donations and gifts and is included in full in the statement of financial activities when receivable. Volunteer time is not included in the financial statements.

Donated services and facilities are included as incoming resources (with an equivalent amount in resources expended) only where the benefit to the charity is reasonably quantifiable, measurable and material. The value placed on these resources is the estimated value to the charity of the service or facility received.

- c) Revenue grants are credited to the statement of financial activities when received or receivable which ever is earlier, unless they relate to a specific future period, in which case they are deferred.
- d) Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.

Where possible resources expended are allocated directly to the activity to which they relate. Costs which cannot be attributed directly to a particular activity, including salary and office related costs, are apportioned on a basis which the Trustees consider appropriate such as the amount of time spent or space occupied.

The main cost categories that cannot be allocated directly, the basis of their allocation and the indicative split between activities are as follows:

Basis of allocation	Staff Costs -	Office Costs	Communicat -
	Average Time %	Time/Space %	ions How used %
Costs of generating funds	28	27	30
Research	21	23	10
Information and Support	26	25	50
Awareness and education	23	23	10
Governance	2	2	-
	<u>100</u>	<u>100</u>	<u>100</u>

- e) Governance costs are the costs associated with the governance arrangements of the charity. These costs are associated with the constitutional and statutory requirements and include any costs associated with the strategic management of the charity's activities.

Costs of generating funds relate to the costs incurred by the charity in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purpose.

Where information about the aims, objectives and projects of the charity is provided to potential beneficiaries, the costs associated with this publicity are allocated to charitable expenditure.

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2015

3. Resources expended

	Costs of generating funds £	Research £	Information and Support £	Awareness and education £	Governance Costs £	2015 Total £	2014 Total £
Research grants payable	-	251,521	-	-	-	251,521	-
Staff costs (Note 5)	75,496	47,137	76,075	76,731	7,315	282,754	223,951
Other staff costs	3,244	1,865	3,223	2,401	110	10,843	4,187
Travel, subsistence & conference fees	1,190	1,938	1,624	1,364	52	6,168	6,124
Trustees development, expenses & meeting costs	-	-	-	-	4,628	4,628	2,632
Fundraising fees	28,039	-	-	-	-	28,039	20,512
Merchandise (Fundraising Materials)	26,609	-	-	-	-	26,609	8,205
Event participation & publicity costs	18,704	-	-	-	-	18,704	7,519
PR & Marketing	-	-	-	9,357	-	9,357	-
Communications	3,162	1,055	5,269	1,054	-	10,540	15,934
Support services	-	-	2,618	-	-	2,618	9,783
Awareness & education projects	-	-	-	52,818	-	52,818	78,824
Information services	-	-	6,772	-	-	6,772	17,411
Office costs	14,386	12,563	13,271	12,032	885	53,137	48,267
Infrastructure development	238	159	636	22,576	-	23,609	26,522
Membership subscriptions	342	426	53	53	18	892	1,408
Legal & professional	97	85	90	82	7,005	7,359	7,249
Insurance	464	405	428	388	29	1,714	1,957
Bank charges	201	175	185	168	12	741	586
Depreciation	1,339	1,169	1,234	1,119	82	4,943	4,499
Total charitable expenditure	173,511	318,498	111,478	180,143	20,136	803,766	485,570

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2015

4. Net movement in funds

This is stated after charging:

	2015 £	2014 £
Depreciation	4,943	4,499
Trustees' remuneration	Nil	Nil
Trustees' reimbursed expenses	3,588	1,912
Auditors remuneration: Audit	<u>5,700</u>	<u>5,500</u>

Trustees' reimbursed expenses represents the reimbursement of travel and subsistence costs totalling £3,588 for 14 members (2014: £1,912 - 13 members) relating to travel and attendance at meetings of the Trustees and representing Sarcoma UK at conferences and events.

5. Staff costs and numbers

	2015 £	2014 £
Salaries and wages	251,511	197,978
Social security costs	24,840	20,682
Pension contributions	<u>6,403</u>	<u>5,291</u>
	<u>282,754</u>	<u>223,951</u>
Total emoluments paid to staff were:	<u>257,914</u>	<u>203,269</u>

One employee earned between £60,000 and £70,000 during the year (2014: £0). Pension costs relating to this employee amounted to £2,575

The average time spent on delivering activities expressed as full-time equivalent employees during the year was as follows:

	2015 No.	2014 No.
Fundraising	2.1	1.3
Research	1.0	1.0
Information & Support Services	1.8	1.6
Awareness & Education	1.8	1.5
Governance	<u>0.2</u>	<u>0.1</u>
	<u>6.9</u>	<u>5.5</u>

6. Taxation

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

Sarcoma UK**Notes to the financial statements****For the year ended 31 March 2015**

7. Tangible fixed assets

	Office Equipment £	Totals £
Cost		
At the start of the period	22,744	22,744
Additions in period	1,646	1,646
	<u>24,390</u>	<u>24,390</u>
At the end of the period		
Depreciation		
At the start of the period	6,778	6,778
Charge for the period	4,943	4,943
	<u>11,721</u>	<u>11,721</u>
At the end of the period		
Net book value		
At the end of the period	<u>12,669</u>	<u>12,669</u>
At the start of the year	<u>15,966</u>	<u>15,966</u>

8. Debtors

	2015 £	2014 £
Deposits & other debtors	10,517	7,011
Prepayments	84,840	29,853
Accrued income	82,779	48,457
	<u>178,136</u>	<u>85,321</u>

9. Creditors : amounts due within one year

	2015 £	2014 £
Trade creditors	5,135	12,313
Other creditors	247	-
Taxation and social security	7,670	7,242
Accruals	10,800	8,166
Grants payable	196,338	90,940
	<u>220,190</u>	<u>118,661</u>

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2015

10. Creditors : amounts due in greater than one year

	2015 £	2014 £
Grants payable	<u>75,183</u>	<u>-</u>

11. Analysis of net assets between funds

	Unrestricted funds £	Designated funds £	Restricted funds £	Total funds £
Fixed assets	3,000	-	9,669	12,669
Net current assets	464,865	410,676	59,442	934,983
Creditors: amounts due in greater than one year	<u>-</u>	<u>(75,183)</u>	<u>-</u>	<u>(75,183)</u>
Net assets at the end of the year	<u>467,865</u>	<u>335,493</u>	<u>69,111</u>	<u>872,469</u>

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2015

12. Movements in funds

	At the start of the year £	Incoming resources £	Outgoing resources £	Transfers £	At the end of the year £
Restricted funds					
Sarcoma Trust	10	-	-	-	10
Infrastructure Development	96,321	-	(27,220)	-	69,101
Research	25,970	49,236	(75,206)	-	-
Total restricted funds	122,301	49,236	(102,426)	-	69,111
Unrestricted funds					
<i>Designated funds</i>					
Research	250,000	-	(174,794)	260,287	335,493
General funds	339,225	915,473	(526,546)	(260,287)	467,865
Total unrestricted	589,225	915,473	(701,340)	-	803,358
Total funds	711,526	964,709	(803,766)	-	872,469

Purposes of designated funds

Research

The amounts designated to research grants in 2014/15, were not fully utilised due to costs being allocated to the restricted fund for research. The transfer to the fund is to increase the fund balance to the total grant awards expected to be awarded in 2015/16.

Purposes of restricted funds

Sarcoma Trust

These funds represent the amounts retained within the Sarcoma Trust after becoming a linked charity with Sarcoma UK.

Infrastructure Development

These funds were given to build the capacity of the organisation and developing its structure and systems in order to be able to establish an on-going sustainable organisation. Any costs and staff time spent associated with the development of Sarcoma UK and establishing the new structure and systems have been allocated against this fund.

Research

These funds are to be used specifically towards research grants, as requested by the donor.